Use of a semi-physiological pharmacokinetic model to investigate the influence of itraconazole on tacrolimus absorption, distribution and metabolism in mice

References

• Anderton MJ, Manson MM, Verschoyle R, et al (2004). Physiological modelling of formulated and crystalline 3,3′-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos 32:632–8
   PubMed Web of Science ®Google Scholar
• Barrett JS, Della Casa Alberighi O, Läer S, et al (2012). Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther 92:40–9
   PubMed Web of Science ®Google Scholar
• Billaud EM, Guillemain R, Tacco F, et al (1998). Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 46:271–2
   PubMed Web of Science ®Google Scholar
• Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. (2007). A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res 13:2768–76
   PubMed Web of Science ®Google Scholar
• Brooks RG, Hofflin JM, Jamieson SW, et al (1985). Infectious complications in heart-lung transplant recipients. Am J Med 79:412–22
   PubMed Web of Science ®Google Scholar
• Brown RP, Delp MD, Lindstedt SL, et al (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407–84
   PubMed Web of Science ®Google Scholar
• Capone D, Gentile A, Imperatore P, et al (1999). Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. Ann Pharmacother 33:1124–5
   PubMed Web of Science ®Google Scholar
• Christians U, Schmidt G, Bader A, et al (1996). Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 41:187–90
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• De Beule K, Van Gestel J. (2001). Pharmacology of itraconazole. Drugs 61:27–37
   PubMed Web of Science ®Google Scholar
• Dummer JS, Montero CG, Griffith BP, et al (1986). Infections in heart-lung transplant recipients. Transplantation 41:725–9
   PubMed Web of Science ®Google Scholar
• Edginton AN, Theil FP, Schmitt W, et al (2008). Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 4:1143–52
   PubMed Web of Science ®Google Scholar
• Filler G, Grygas R, Mai I, et al (1997). Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant 12:1668–71
   PubMed Web of Science ®Google Scholar
• Fung JJ. (2004). Tacrolimus and transplantation: a decade in review. Transplantation 77:S41–3
   PubMed Web of Science ®Google Scholar
• Furlan V, Parquin F, Penaud JF, et al (1998). Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. Transplant Proc 30:187–8
   PubMed Web of Science ®Google Scholar
• Furlan V, Perello L, Jacquemin E, et al (1995). Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. Transplantation 59:1217–18
   PubMed Web of Science ®Google Scholar
• Grant SM, Clissold SP. (1989). Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37:310–44
   PubMed Web of Science ®Google Scholar
• Gupta AK, Adamiak A, Chow M. (2002). Tacrolimus: a review of its use for the management of dermatoses. J Eur Acad Dermatol Venereol 16:100–14
   PubMed Web of Science ®Google Scholar
• Hebert MF, Lam AY. (1999). Diltiazem increases tacrolimus concentrations. Ann Pharmacother 33:680–2
   PubMed Web of Science ®Google Scholar
• Heykants J, Van Peer A, Van de Velde V, et al (1989). The clinical pharmacokinetics of itraconazole: an overview. Mycoses 32:67–87
   PubMed Web of Science ®Google Scholar
• Hoensch H, Woo CH, Raffin SB, et al (1976). Oxidative metabolism of foreign compounds in rat small intestine: cellular localization and dependence on dietary iron. Gastroenterology 70:1063–70
   PubMed Web of Science ®Google Scholar
• Hooks MA. (1994). Tacrolimus, a new immunosuppressant – a review of the literature. Ann Pharmacother 28:501–11
   PubMed Web of Science ®Google Scholar
• Hu TM, Hayton WL. (2001). Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci 3:30–43
   Google Scholar
• Hu ZY, Lu J, Zhao Y. (2014). A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. Br J Pharmacol 171:2778–89
   PubMed Web of Science ®Google Scholar
• Isoherranen N, Kunze KL, Allen KE, et al (2004). Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32:1121–31
   PubMed Web of Science ®Google Scholar
• Iwasaki K. (2007). Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 22:328–35
   PubMed Web of Science ®Google Scholar
• Jeong H, Chiou WL. (2006). Role of P-glycoprotein in the hepatic metabolism of tacrolimus. Xenobiotica 36:1–13
   PubMed Web of Science ®Google Scholar
• Kagan L, Gershkovich P, Wasan KM, et al (2011). Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data. AAPS J 13:255–64
   PubMed Web of Science ®Google Scholar
• Khalil F, Läer S. (2011). Physiologically based pharmacokinetic modelling: methodology, applications, and limitations with a focus on its role in paediatric drug development. J Biomed Biotechnol 2011:137–43
   Google Scholar
• Kramer MR, Amital A, Fuks L, et al (2011). Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. Clin Transplant 25:E163–7
   PubMed Web of Science ®Google Scholar
• Kramer MR, Denning DW, Marshall SE, et al (1991). Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis 144:552–6
   PubMed Web of Science ®Google Scholar
• Kramer MR, Marshall SE, Starnes VA, et al (1993). Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med 153:2010–16
   PubMedGoogle Scholar
• Kunze KL, Nelson WL, Kharasch ED, et al (2006). Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab Dispos 34:583–90
   PubMed Web of Science ®Google Scholar
• Leather H, Boyette RM, Tian L, et al (2006). Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 12:325–34
   PubMed Web of Science ®Google Scholar
• Lin JH, Chiba M, Baillie TA. (1999). Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135–58
   PubMed Web of Science ®Google Scholar
• Lin YS, Dowling AL, Quigley SD, et al (2002). Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162–72
   PubMed Web of Science ®Google Scholar
• Lu XF, Bi K, Chen X. (2016). Physiologically based pharmacokinetic model of docetaxel and interspecies scaling: comparison of simple injection with folate receptor-targeting amphiphilic copolymer-modified liposomes. Xenobiotica 17:1–12
   Google Scholar
• Marchetti S, Mazzanti R, Beijnen JH, et al (2007). Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12:927–41
   PubMed Web of Science ®Google Scholar
• Masuda S, Inui K. (2006). An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 112:184–98
   PubMed Web of Science ®Google Scholar
• Meno-Tetang GM, Li H, Mis S, et al (2006). Physiologically based pharmacokinetic modelling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 34:1480–7
   PubMed Web of Science ®Google Scholar
• Michalets EL. (1998). Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84–112
   PubMed Web of Science ®Google Scholar
• Nara M, Takahashi N, Miura M, et al (2013). Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants. Eur J Clin Pharmacol 69:1321–9
   PubMed Web of Science ®Google Scholar
• Nestorov I. (2007). Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 3:235–49
   PubMed Web of Science ®Google Scholar
• Obach RS, Zhang QY, Dunbar D, et al (2001). Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab Dispos 29:347–52
   PubMed Web of Science ®Google Scholar
• Outeda Macías M, Salvador P, Hurtado JL, et al (2000). Tacrolimus-itraconazole interaction in a kidney transplant patient. Ann Pharmacother 34:536
   PubMed Web of Science ®Google Scholar
• Peng CC, Shi W, Lutz JD, et al (2012). Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals. Drug Metab Dispos 40:426–35
   PubMed Web of Science ®Google Scholar
• Peters DH, Fitton A, Plosker GL, et al (1993). Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 46:746–94
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A. (2012). Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 92:50–61
   PubMed Web of Science ®Google Scholar
• Sharma V, McNeill JH. (2009). To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157:907–21
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23
   PubMed Web of Science ®Google Scholar
• Sinha VK, Snoeys J, Osselaer NV, et al (2012). From preclinical to human–prediction of oral absorption and drug–drug interaction potential using physiologically based pharmacokinetic (PBPK) modelling approach in an industrial setting: a workflow by using case example. Biopharm Drug Dispos 33:111–21
   PubMed Web of Science ®Google Scholar
• Slaughter RL, Edwards DJ. (1995). Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 29:619–24
   PubMed Web of Science ®Google Scholar
• Scott LJ, Mckeage K, Keam SJ, et al (2003). Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 63:1247–97
   PubMed Web of Science ®Google Scholar
• Shon JH, Yoon YR, Hong WS, et al (2005). Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 78:191–201
   PubMed Web of Science ®Google Scholar
• Templeton I, Peng CC, Thummel KE, et al (2010). Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther 88:499–505
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues . Proc Natl Acad Sci USA 84:7735–8
   PubMed Web of Science ®Google Scholar
• Togashi M, Niioka T, Komatsuda A, et al (2015). Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease. Eur J Clin Pharmacol 71:1091–7
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. (2000). Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38:111–80
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Swaminathan A, Prasad T, et al (1995). Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404–30
   PubMed Web of Science ®Google Scholar
• Woo DK, James WD. (2005). Topical tacrolimus: a review of its uses in dermatology. Dermatitis 16:6–21
   PubMed Web of Science ®Google Scholar
• Zhao P, Zhang L, Grillo JA, et al (2011). Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89:259–67
   PubMed Web of Science ®Google Scholar